Included in the formulation
АТХ:A.03.A.B.06 Otilonium bromide
Pharmacodynamics:The drug competitively blocks m-holinoretseptory, mainly in the gastrointestinal tract. This leads to a decrease in the tone of the smooth muscles of the internal organs. Ha tetrameric ammonium compound. The drug also blocks Ca2+ channels, which reduces the concentration of Ca2+ in smooth muscles, as a result, the tone of smooth muscles decreases.
Pharmacokinetics:After oral administration, the preparation is absorbed in a very small amount in the intestine. High degree of distribution in the smooth muscles of the rectum. Excreted through the bile ducts (95-97%). Excretion is long.
Indications:- dyskinesia of the gastrointestinal tract;
- irritable bowel syndrome (mucous colitis), gastritis, gastroduodenitis, enteritis, esophagitis;
- spastic conditions;
- preparation of patients for endoscopy of the gastrointestinal tract.
XI.K20-K31.K20 Esophagitis
XI.K20-K31.K29 Gastritis and duodenitis
XI.K50-K52.K52 Other non-infectious gastroenteritis and colitis
XI.K55-K63.K58 Irritable Bowel Syndrome
XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified
Contraindications:hypersensitivity;
- Children's age up to 3 years.
Carefully:- glaukoma;
- diseases of the cardiovascular system;
- thyrotoxicosis;
- reflux esophagitis;
- stenosis of the pylorus;
- kidney disease;
- Dow diseaseon;
- central paralysis in children;
- liver disease;
- atony of the gastrointestinal tract;
- hypertrophy of the prostate.
Pregnancy and lactation:Category FDA not determined. During pregnancy and during lactation, the application is possible when the intended benefit exceeds the risk of side effects.
Dosing and Administration:Orally 20-40 mg 2-3 times a day.
Rectal 20 mg 3 times a day.
Side effects:- allergic reactions;
- paresis of accommodation;
- dry mouth;
- mydriasis;
- drowsiness.
Overdose:Shakiness of gait, impaired vision, difficulty breathing, dry mucous membranes, dizziness, muscle weakness, fever.
Treatment: slow intravenous injection of physostigmine - 0.5-2 mg at a rate of not more than 1 mg per minute, not more than 5 mg per day, or neostigmine methylsulfate intramuscularly - 0.5-1 mg every 2-3 hours, intravenously - 0.5-2 mg (repeat if necessary).
Interaction:Antacids antidiarrhoeal drugs (adsorbents) - a decrease in the absorption of otilonium bromide, a decrease in therapeutic effectiveness.
Ketoconazole - the drug slows the absorption of ketoconazole.
Medicines with anticholinergic activity - the enhancement of the m-cholinoblocking effect, up to the paralytic ileus.
When administered simultaneously with potassium chloride - increased severity of damage to the gastrointestinal tract with potassium chloride.
Special instructions:Impact on the ability to drive vehicles and manage mechanisms
The drug may cause dizziness, drowsiness, apply with caution.